Apo-Lamivudine-Zidovudine 150 mg (Lamivudine TABLET) 150 MG

APO-LAMIVUDINE-ZIDOVUDINE 150 MG tablets combine lamivudine and zidovudine for HIV treatment. This oral medication is designed to manage HIV infection as part of a comprehensive treatment plan.

Strength

150 MG

Pack Size

100

Manufacturer / TM Owner

APOTEX INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

APO-LAMIVUDINE-ZIDOVUDINE 150 MG tablets are used in the treatment of HIV infection. This combination medication helps to control the virus and improve immune function. It is typically prescribed as part of a broader antiretroviral therapy regimen to manage HIV and reduce the risk of disease progression.

Side Effects

Common effects of APO-LAMIVUDINE-ZIDOVUDINE 150 MG tablets may include fatigue, headache, and nausea. Some individuals might experience changes in appetite or mild gastrointestinal discomfort. These effects vary and are not experienced by everyone.

Precautions & Warnings

APO-LAMIVUDINE-ZIDOVUDINE 150 MG tablets should be handled with care. It is important to follow the prescribed dosage and consult a healthcare provider before starting or stopping the medication. Regular monitoring may be necessary to assess treatment effectiveness and side effects.

Avoid Interactions

APO-LAMIVUDINE-ZIDOVUDINE 150 MG tablets may interact with other medications, including certain antiretrovirals and drugs metabolized by the liver. Alcohol and other substances that affect liver function should be avoided. Always inform your healthcare provider about all medications you are taking.

Frequently Asked Questions

APO-LAMIVUDINE-ZIDOVUDINE 150 MG tablets are used to treat HIV infection as part of a combination therapy.

APO-LAMIVUDINE-ZIDOVUDINE 150 MG tablets are taken orally, typically as prescribed by a healthcare provider.

Common side effects may include fatigue, headache, and nausea, though not everyone experiences these effects.

APO-LAMIVUDINE-ZIDOVUDINE 150 MG may interact with other medications, so it is important to consult a healthcare provider before combining it with other drugs.

Precautions include following the prescribed dosage, avoiding alcohol, and regular monitoring as advised by a healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.